Medical device and MedTech insights, news, tips and more
Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain
October 13, 2022
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS) system.
Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients. It was developed to address the variability in pain from patient to patient and to help patients optimize and maintain long-term pain relief and improved quality of life. The Senza HFX iQ system is comprised of the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger and HFX App and will launch with algorithms specifically for treating chronic back and leg pain, including non-surgical back pain and painful diabetic neuropathy.
Senza HFX iQ is digitally-enabled and designed to optimize care by collecting patient data and guiding the patient through a customized treatment pathway. It provides several key advantages over other SCS systems:
- Patients start on the program most likely to provide pain relief, based on the HFX Algorithm™, which was built from more than 20 million datapoints and 80,000 implanted patients;
- Recommends customized therapy adjustments informed by patient inputs on the HFX App, including % pain relief, pain score, change in activity levels and change in pain medications;
- Directly adjusts the pain relief program on the patient’s IPG from the HFX App on their smartphone, without the need for a separate manual remote;
- Captures patient and device data to enable sharing of patient-level outcomes with treating and referring physicians; and
- Provides a connected, digital environment around a patient’s therapy that will allow for future updates to the HFX Algorithm, as well as new features and capabilities for patients and providers.
“HFX iQ is designed to improve the consistency of pain relief and is the only SCS system that truly personalizes care,” stated D. Keith Grossman, Chairman and CEO of Nevro. “Pain is variable from patient to patient and over time. Using the big data from our HFX Cloud patient database, our unique HFX Algorithm was developed to identify those programs where patients have been more likely to get relief in the real world. HFX iQ takes direct input from each patient on their pain and quality of life measures to get smarter over time and recommend program changes. HFX iQ utilizes our superior high-frequency 10 kHz Therapy platform, which has been proven in clinical trials and is further supported by real-world evidence from more than 90,000 implanted patients. With HFX iQ, our goal is to provide physicians and patients the personalization needed to achieve and maintain the best possible long-term outcomes. We believe HFX iQ represents the future of SCS therapy.”
Nevro will initiate a limited release of Senza HFX iQ in the U.S. this quarter, with a broad U.S. market launch planned for early 2023. In addition to the U.S. approval for HFX iQ, Nevro has submitted for approval in Europe.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 90,000 patients globally. Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.
See Full Press Release at the Source: Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain
Press Release by: Nevro Corp
Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.